Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM® in Patients With Acute Exacerbation of Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms PRISMA-3
- Sponsors Rovi
- 26 Jul 2017 According to a Rovi media release, first patient has been recruited in this study.
- 17 May 2017 Status changed from planning to recruiting.
- 16 Feb 2017 According to a Rovi media release, data from this study will support Risperidone ISM approval in USA and Europe.